In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Juno Therapeutics' IPO nets $283mm

30 Dec 2014

Executive Summary

Just one year after its launch, Juno Therapeutics Inc. (chimeric antigen receptor T-cell (CART) technology for cancer drug development) netted $283mm through its initial public offering of 12.7mm shares (including the overallotment) at $24. The IPO (one of the largest for a US biopharma company in 2014) was greatly upsized: after filing in November, Juno set an initial range earlier this month of 9.25mm shares at $15-18, and a few days before pricing increased the potential per-share price to $21-23.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By